-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Author Archive: Abigail Hirsch
Premature Infant Summit: Born Too Soon
Each year, more than half a million babies are born prematurely in the United States or roughly one in eight births. The toll prematurity takes on infant health and on families and society is profound. Babies born prematurely may be at risk of severe health problems. Some of the leading causes of infant death include low birth weight and prematurity. Despite these staggering statistics, the “voice” of premature patients and their families is often underrepresented Read More >
Industry Regulatory Issues to be Highlighted at 2012 BIO International Convention
In the words of BIO’s Andrew Emmett, Managing Director, Science & Regulatory Affairs, ‘2012 is shaping up to be a momentous year for FDA reform.’ From the reauthorization of the Prescription Drug User Fee Act (PDUFA V) to modernizing and expediting the approval of new drugs and biologics, implementing the new biosimilars pathways and addressing the growing global drug shortage crisis, all eyes are on the current regulatory environment and its role in supporting innovation. Read More >
2012 Orphan Disease Forum: Addressing Today’s Opportunities and Challenges
If all of the people with rare disease lived in one country, it would be the world’s third most populous country! Through dedicated companies such as the National Organization for Rare Disorders (NORD) and Centric Health Resources, the pressing issue of orphan diseases and its patients are being addressed. A rare disease is defined by any disease affecting fewer than 200,000 Americans. There are nearly 7,000 such diseases affecting over 350 million people worldwide. Furthermore, Read More >
2012 MassBioEd Innovative School of the Year – Norton High School
Massachusetts is home to the full ecosystem of life sciences—including our world class academic institutions and medical centers, a vibrant venture capital community, hundreds of biotech companies of all sizes, contract research and manufacturing organizations, and service organizations supporting the industry. It is no wonder then that eleven years ago MassBio established the Massachusetts Biotechnology Foundation to promote biotechnology education and workforce development programs. Each year, the Foundation awards the Innovative School of the Year Read More >
Abbott Laboratories: Keys for Partnering Success at the BIO International Convention
Thinking of hosting pre-qualified meetings at your BIO Exhibition booth during the 2012 BIO International Convention? Abbott Laboratories did just that at last year’s Convention and learned what it takes to succeed and secure high-quality leads. “The greatest value of partnering within our booth is that it allows us to drive traffic, activity and interest within our booth space,” said Michelle Calhoun, Abbott’s contract manufacturing sales and marketing director. During the 2011 Convention, Abbott hosted Read More >




